Majid Kazmi

Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Avila Therapeutics, Inc. researches and develops covalent drugs. The company was founded in 2007 and is headquartered in Summit, NJ.

Aleta Biotherapeutics, Inc. engages in the immuno-oncology service that focuses on transforming cellular therapeutics. It allows broad spectrum of cancer indication to be targeted including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb and is headquartered in Natick, MA.

Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA.

Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA.

Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff.

GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France.

Pheno Therapeutics Ltd. operates as a biotechnology company. The firm develops remyelinating therapies for the unmet need for a neuroprotective therapy for multiple sclerosis. The company was founded on October 31, 2018 and is headquartered in Edinburgh, the United Kingdom.

Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA.

Contura Ltd. specializes in the distribution and sale of healthcare products, both in pharmaceuticals and medical devices. The firm focuses in the fields of urology and urogynaecology. Its products include bulkamid, cystistat, and aquamid. The company was founded by Henry Geoffrey McMillan in 2000 and is headquartered in London, the United Kingdom.

NeRRe Therapeutics Ltd. provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity. It develops neurokinin receptor antagonists acquired from GlaxoSmithKline. The company was founded by Emiliangelo Ratti and Mike Trower in 2012 and is headquartered in Stevenage, the United Kingdom.

Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom.

Luxfold S.A. designs and engineers protein structures. It offers protein three-dimensional structure. The company is headquartered in Luxembourg.

Abingworth Management, Inc. invests in life sciences and biomedical companies. The firm's investment in enables technologies, devices and instrumentation as well as companies developing products in therapeutic areas. The company was founded in 1973 and is headquartered in Menlo Park, CA.

Nalu Medical, Inc. is a medical technology company, which develops, manufactures, and commercializes invasive solutions for patients with chronic neuropathic pain. It markets Nalu neurostimulation system that delivers gentle electrical pulses to the nervous system to modulate pain signals to the brain. The company was founded by Keegan Harper, Lee Hartley, Mike Partsch, and Daniel Pivonka in October 28, 2014 and is headquartered in Carlsbad, CA.

Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey.

Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA.

MQ: Transforming Mental Health is a British company that focuses on driving mental health research to better understand, diagnose, and treat mental illness. The non-profit company is based in London, UK. The company brings people and researchers together to make groundbreaking progress in this field. The company advocates for transforming mental health and is supported by a scientific network. The company is honing their focus on the areas that are most vital and can have the greatest impact on the mental health landscape.

PartsSource, Inc. sells replacement medical parts for hospital equipment. The firm operates proprietary technology platform eliminates friction from the healthcare supply chain by delivering evidence-based decision support and workflow automation. The company was founded by A. Ray Dalton in 2001 and is headquartered in Aurora, OH.

Nicoventures Trading Ltd. researches, develops, manufactures and delivers tobacco harm reduction products and services. The firm provides innovative and sustainable solutions to global problems arising from smoking and smoking-related illnesses. The company develops ortfolio of products and services focused on smoking cessation and harm reduction, including user-friendly nicotine delivery systems and patient-focused smoking cessation and support services. The company was founded by Christopher John Lord and David Thomas Newns in September 2008 and is headquartered in Manchester, the United Kingdom.

Cutfield Freeman & Co. Ltd. provides independent advice on mining finance such as joint ventures, project finance, mergers and acquisitions, private fund raising, and corporate restructuring. The firm also develops and implements strategies to address complex mining finance challenges. The company was founded in 2000 and is headquartered in London, the United Kingdom.

KaNDy Therapeutics Ltd. engages in the provision of a treatment of chronic debilitating female sex-hormone related conditions. Its product is NT-814 a non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms. The company was founded by Dr. Mike Trower and Mary Kerr in 2017 and is headquartered in Stevenage, the United Kingdom.

NeRRe Therapeutics Holdings Ltd. is a British biotechnology company founded in 2017. The private company is based in Stevenage, UK. The company is engaged in research and development of biotechnology.

Iterum Therapeutics International Ltd. engages in the development of clinical-stage pharmaceutical products. The company was founded in 2015 and is headquartered in Dublin, Ireland.

Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France.

AdBio Partners SAS (AdBio Partners) is a venture capital firm founded in 2015. The firm is headquartered in Paris, France.

Alderaan Biotechnology SAS operates as preclinical stage firm, that develops monoclonal antibodies for the treatment of cancer. The company was founded by Daniel Olive and Armand Bensussan on July 17, 2017 and is headquartered in Paris, France.

Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France.

Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020.

DiogenX SAS engages in the discovery and development of biologics therapeutics options of Diabetic patients. It operates in Diabetes preclinical stage business segment. The company was founded by Benjamin Charles, Patrick Collombat and Jean Pascal Tranié on December 24, 2019 and is headquartered in Marseille, France.